Nintedanib has been shown to slow disease progression in patients with idiopathic pulmonary fibrosis (IPF). It was approved by the National Institute for Health and Care Excellence (NICE) in January 2016 for I...
Παρασκευή 3 Νοεμβρίου 2017
Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Abstract Objectives To investigate factors related to reasoning skills in 434 school children aged 5–9 years. Methods The Leiter Interna...
-
Neutrophilic urticarial dermatosis as a presenting feature of systemic juvenile idiopathic arthritisPediatric Dermatology, EarlyView.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.